» Articles » PMID: 29464791

Comparing Pharmacological Treatments for Cocaine Dependence: Incorporation of Methods for Enhancing Generalizability in Meta-analytic Studies

Overview
Specialty Psychiatry
Date 2018 Feb 22
PMID 29464791
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Few head-to-head comparisons of cocaine dependence medications exist, and combining data from different randomized controlled trials (RCTs) is fraught with methodological challenges including limited generalizability of the RCT findings. This study applied a novel meta-analytic approach to data of cocaine dependence medications.

Methods: Data from 4 placebo-controlled RCTs (Reserpine, Modafinil, Buspirone, and Ondansetron) were obtained from the National Institute of Drug Abuse Clinical Trials Network (n = 456). The RCT samples were weighted to resemble treatment-seeking patients (Treatment Episodes Data Set-Admissions) and individuals with cocaine dependence in general population (National Survey on Drug Use and Health). We synthesized the generalized outcomes with pairwise meta-analysis using individual-level data and compared the generalized outcomes across the 4 RCTs with network meta-analysis using study-level data.

Results: Weighting the data by the National Survey on Drug Use and Health generalizability weight made the overall population effect on retention significantly larger than the RCT sample effect. However, there was no significant difference between the population effect and the RCT sample effect on abstinence. Weighting changed the ranking of the effectiveness across treatments.

Conclusions: Applying generalizability weights to meta-analytic studies is feasible and potentially provides a useful tool in assessing comparative effectiveness of treatments for substance use disorders in target populations.

Citing Articles

Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia.

Hong H, Liu L, Mojtabai R, Stuart E BMC Med Res Methodol. 2023; 23(1):150.

PMID: 37365521 PMC: 10294408. DOI: 10.1186/s12874-023-01958-w.


Threats to external validity in the neuroprediction of substance use treatment outcomes.

Gancz N, Forster S Am J Drug Alcohol Abuse. 2022; 49(1):5-20.

PMID: 36099534 PMC: 9974755. DOI: 10.1080/00952990.2022.2116712.


Two-stage matching-adjusted indirect comparison.

Remiro-Azocar A BMC Med Res Methodol. 2022; 22(1):217.

PMID: 35941551 PMC: 9358807. DOI: 10.1186/s12874-022-01692-9.


Clinical Trial Generalizability Assessment in the Big Data Era: A Review.

He Z, Tang X, Yang X, Guo Y, George T, Charness N Clin Transl Sci. 2020; 13(4):675-684.

PMID: 32058639 PMC: 7359942. DOI: 10.1111/cts.12764.


Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies.

Susukida R, Crum R, Hong H, Stuart E, Mojtabai R Int J Methods Psychiatr Res. 2018; 27(4):e1609.

PMID: 29464791 PMC: 6103900. DOI: 10.1002/mpr.1609.

References
1.
Shorter D, Domingo C, Kosten T . Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drugs. 2014; 20(1):15-29. DOI: 10.1517/14728214.2015.985203. View

2.
Johnson B, Roache J, Ait-Daoud N, Javors M, Harrison J, Elkashef A . A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006; 84(3):256-63. DOI: 10.1016/j.drugalcdep.2006.02.011. View

3.
Mansournia M, Altman D . Inverse probability weighting. BMJ. 2016; 352:i189. DOI: 10.1136/bmj.i189. View

4.
Carroll K, Fenton L, Ball S, Nich C, Frankforter T, Shi J . Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2004; 61(3):264-72. PMC: 3675448. DOI: 10.1001/archpsyc.61.3.264. View

5.
Hoertel N, Le Strat Y, Lavaud P, Dubertret C, Limosin F . Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013; 74(3):265-70. DOI: 10.4088/JCP.12m07935. View